AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8305999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 8305999 — intervention group
Group type: COMPARATOR
Intervention: No mammography screening (unscreened)
Number of subjects: 0
Study 3315825 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n = 11)
Number of subjects: 19
Study 3315825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 19
Study 3315825 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n = 5)
Number of subjects: 19
Study 3315825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 19
Study 31441525 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat health education programme (3 months)
Number of subjects: 120
Study 27715322 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention using a pedal exerciser
Number of subjects: 58
Study 27715322 — intervention group
Group type: COMPARATOR
Intervention: Standard medical and pharmacological care (Control)
Number of subjects: 58
Study 26312597 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide therapy (20 µg twice daily) for 1 week
Number of subjects: 16
Study 26312597 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 16
Study 26312597 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide therapy
Number of subjects: 16
Study 26312597 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide therapy and Standard treatment (control)
Number of subjects: 16
Study 23017610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) program, three sessions a week for 20 weeks
Number of subjects: 55
Study 23017610 — intervention group
Group type: COMPARATOR
Intervention: Control group (health and cultural information classes for 20 weeks)
Number of subjects: 55
Study 21498114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO(3)) ingestion (0.3 g kg(‐1) body mass)
Number of subjects: 7
Study 21498114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 7
Study 19140238 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glyceryl trinitrate
Number of subjects: 74
Study 19140238 — intervention group
Group type: COMPARATOR
Intervention: 100 mg vitamin C (placebo)
Number of subjects: 74
Study 17711595 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (ECS) worn daily on the DVT-affected leg for 2 years
Number of subjects: 800
Study 17711595 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive) stockings worn daily on the DVT-affected leg for 2 years
Number of subjects: 800
Study 17711595 — intervention group
Group type: EXPERIMENTAL
Intervention: ECS
Number of subjects: 800
Study 15154856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular infusion of a combination of bradykinin, serotonin, histamine, and prostaglandin E2
Number of subjects: 15
Study 15154856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12464382 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate mailout (two letters)
Number of subjects: 2393
Study 12464382 — intervention group
Group type: COMPARATOR
Intervention: Joint mailout (one letter)
Number of subjects: 2393
Study 9821565 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mol/L sodium lactate
Number of subjects: 0
Study 9821565 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3% sodium chloride)
Number of subjects: 0
Study 9821565 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 0
Study 7545257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermochemoradiotherapy (HCR)
Number of subjects: 66
Study 7545257 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CR)
Number of subjects: 66
Study 2506844 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrophenoxine (CPH) 2 g/day for 8 weeks
Number of subjects: 50
Study 2506844 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 8 weeks
Number of subjects: 50
Study 823433 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% amino acid solution
Number of subjects: 10
Study 823433 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 10
Study 6101516 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol maintained until the day of surgery, half the usual dose given 2 hours prior to surgery, and intravenous propranolol administered every four hours postoperatively (group IV, n=19)
Number of subjects: 54
Study 6101516 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol abruptly withdrawn 48 hours prior to surgery (group II, n=17)
Number of subjects: 54
Study 6101516 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol abruptly withdrawn 10 hours prior to surgery (group III, n=18)
Number of subjects: 54
Study 6101516 — intervention group
Group type: COMPARATOR
Intervention: No propranolol therapy (group I, n=17)
Number of subjects: 54
Study 31707324 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-29.9 kg/m2)
Number of subjects: 14534
Study 31707324 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese class I (BMI 30-34.9 kg/m2)
Number of subjects: 14534
Study 31707324 — intervention group
Group type: COMPARATOR
Intervention: Underweight/normal weight (BMI <25 kg/m2)
Number of subjects: 14534
Study 30580198 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytics
Number of subjects: 482
Study 30580198 — intervention group
Group type: EXPERIMENTAL
Intervention: BISS anxiety subscale
Number of subjects: 482
Study 30580198 — intervention group
Group type: EXPERIMENTAL
Intervention: BISS anxiety score at baseline
Number of subjects: 482
Study 28377173 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1 μg daily for 4 months
Number of subjects: 82
Study 28377173 — intervention group
Group type: COMPARATOR
Intervention: Standard asthma treatment only
Number of subjects: 82
Study 25415205 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sedentary time on weekdays
Number of subjects: 230
Study 25415205 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured sedentary time
Number of subjects: 230
Study 25415205 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sedentary time
Number of subjects: 230
Study 25415205 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer-measured sedentary time on weekdays vs. weekend days
Number of subjects: 230
Study 23319437 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (ARG; 0.075 g·kg‐1 body mass)
Number of subjects: 15
Study 23319437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study 23319437 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (ARG)
Number of subjects: 15
Study 21608216 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) for 5 years (TGP1 group)
Number of subjects: 96
Study 21608216 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) for 1-5 years (TGP2 group)
Number of subjects: 96
Study 21608216 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched patients)
Number of subjects: 96
Study 19711141 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 630
Study 19711141 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 630
Study 17370493 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point magnetotherapy (sticking magnetic bead of 66 gauss each piece with no pressing)
Number of subjects: 60
Study 17370493 — intervention group
Group type: COMPARATOR
Intervention: Auricular sticking of Vaccaria seed with no pressing
Number of subjects: 60
Study 15331203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (1000 kcal per day, protein:carbohydrate:fat = 25:40:35)
Number of subjects: 22
Study 15331203 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (1000 kcal per day, protein:carbohydrate:fat = 25:65:10)
Number of subjects: 22
Study 12003104 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (11.3±6.9 kg after 1 year)
Number of subjects: 34
Study 12003104 — intervention group
Group type: COMPARATOR
Intervention: Before weight loss measurements
Number of subjects: 34
Study 12003104 — intervention group
Group type: EXPERIMENTAL
Intervention: After weight loss measurements
Number of subjects: 34
Study 9457092 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warfarin and active aspirin (WA)
Number of subjects: 5499
Study 9457092 — intervention group
Group type: COMPARATOR
Intervention: Active warfarin (W)
Number of subjects: 5499
Study 9457092 — intervention group
Group type: COMPARATOR
Intervention: Active aspirin (A)
Number of subjects: 5499
Study 9457092 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 5499
Study 9457092 — intervention group
Group type: COMPARATOR
Intervention: Warfarin or aspirin
Number of subjects: 5499
Study 7616989 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg twice daily)
Number of subjects: 77
Study 7616989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 7616989 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 77
Study 2911965 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic 12 msec truncated exponential waveform
Number of subjects: 21
Study 2911965 — intervention group
Group type: COMPARATOR
Intervention: Monophasic truncated exponential waveform
Number of subjects: 21
Study 201111 — intervention group
Group type: EXPERIMENTAL
Intervention: D-thyroxin (4 mg/die)
Number of subjects: 21
Study 201111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30624885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicyclic RGD peptides (e.g., CT3HPQcT3RGDcT3, CT3HPQCT3RGDcT3, CT3HSQCT3RGDcT3)
Number of subjects: 672
Study 30624885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy5-labeled bicycle CT3HPQcT3RGDcT3
Number of subjects: 672
Study 30624885 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD 'knottin' peptide
Number of subjects: 672
Study 30624885 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro staining of HT29 cells with Cy5-labeled bicycles
Number of subjects: 672
Study 28651514 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution (Plasma-Lyte 148)
Number of subjects: 11000
Study 28651514 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride)
Number of subjects: 11000
Study 26049181 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/d hydrocortisone intravenous infusion lasting for 2 hours (control group)
Number of subjects: 79
Study 26049181 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.33 mg/h hydrocortisone per hour with an intravenous pump (research group)
Number of subjects: 79
Study 23915054 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend condition (target letters in specified color)
Number of subjects: 3
Study 23915054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignore condition (letters in different color)
Number of subjects: 3
Study 21153471 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 280
Study 21153471 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fascia sling procedure
Number of subjects: 280
Study 18586692 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of insight at baseline
Number of subjects: 0
Study 18586692 — intervention group
Group type: EXPERIMENTAL
Intervention: More positive medication attitudes
Number of subjects: 0
Study 18586692 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in insight scores over time
Number of subjects: 0
Study 18586692 — intervention group
Group type: EXPERIMENTAL
Intervention: Change toward more positive medication attitudes
Number of subjects: 0
Study 16107544 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed cognitive-behavioral intervention
Number of subjects: 40
Study 16107544 — intervention group
Group type: COMPARATOR
Intervention: PedsQL 4.0
Number of subjects: 40
Study 15220594 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated silicone breast implant rupture
Number of subjects: 271
Study 15220594 — intervention group
Group type: COMPARATOR
Intervention: Intact silicone breast implants
Number of subjects: 271
Study 12208405 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg given as twice daily subcutaneous injections)
Number of subjects: 1326
Study 12208405 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 1326
Study 9643402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuses with ARED flow
Number of subjects: 88
Study 9643402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuses born alive with ARED flow
Number of subjects: 88
Study 9643402 — intervention group
Group type: EXPERIMENTAL
Intervention: Group with absent end-diastolic flow at first examination and then reversed flow until delivery
Number of subjects: 88
Study 7814306 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 6
Study 7814306 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise condition
Number of subjects: 6
Study 7814306 — intervention group
Group type: COMPARATOR
Intervention: Less vigorous antecedent conditions
Number of subjects: 6
Study 7814306 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise before vocational task
Number of subjects: 6
Study 2759546 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide‐5‐mononitrate (1-hour post-administration)
Number of subjects: 19
Study 2759546 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide‐5‐mononitrate (7-day administration)
Number of subjects: 19
Study 2759546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 356719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (1-2 mg t.i.d.)
Number of subjects: 52
Study 356719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin + Hydrochlorothiazide (25 mg daily for 3 weeks)
Number of subjects: 52
Study 356719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin + Hydrochlorothiazide + Clonidine (low doses for 6 weeks)
Number of subjects: 52
Study 356719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31769875 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 215
Study 31769875 — intervention group
Group type: COMPARATOR
Intervention: Platinum-pemetrexed
Number of subjects: 215
Study 31769875 — intervention group
Group type: COMPARATOR
Intervention: Cobas plasma
Number of subjects: 215
Study 31769875 — intervention group
Group type: COMPARATOR
Intervention: ddPCR
Number of subjects: 215
Study 31769875 — intervention group
Group type: COMPARATOR
Intervention: NGS
Number of subjects: 215
Study 30706944 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization statistics
Number of subjects: 0
Study 29349510 — intervention group
Group type: EXPERIMENTAL
Intervention: Early preventive rehabilitation lasting 12 weeks
Number of subjects: 76
Study 29349510 — intervention group
Group type: COMPARATOR
Intervention: Current standard care with no formal shoulder exercise
Number of subjects: 76
Study 27194393 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulated modified constraint-induced movement therapy (SR-mCIMT)
Number of subjects: 86
Study 27194393 — intervention group
Group type: COMPARATOR
Intervention: Conventional functional rehabilitation
Number of subjects: 86
Study 27194393 — intervention group
Group type: COMPARATOR
Intervention: Modified constraint-induced movement therapy (mCIMT)
Number of subjects: 86
Study 25208853 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention promoting healthy eating and physical activity
Number of subjects: 8
Study 25208853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 22240553 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression garments worn continuously for 24 hours after initial 40-km time trial
Number of subjects: 14
Study 22240553 — intervention group
Group type: COMPARATOR
Intervention: Placebo garment (noncompressive) worn continuously for 24 hours after initial 40-km time trial
Number of subjects: 14
Study 22240553 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression garments
Number of subjects: 14
Study 22240553 — intervention group
Group type: COMPARATOR
Intervention: Placebo garment
Number of subjects: 14
Study 20558084 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-directed therapy (rituximab and intravenous immune globulin (IVIG), or IVIG alone)
Number of subjects: 116
Study 20558084 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful depletion of DSA
Number of subjects: 116
Study 20558084 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for DSA
Number of subjects: 116
Study 20558084 — intervention group
Group type: COMPARATOR
Intervention: No DSA
Number of subjects: 116
Study 17368327 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 48
Study 17368327 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 48
Study 15825576 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol application of Quixil sealant at the operative site
Number of subjects: 64
Study 15825576 — intervention group
Group type: COMPARATOR
Intervention: Merocel nasal packing
Number of subjects: 64
Study 11996160 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 6
Study 11996160 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 6
Study 10071982 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1250 mg/m2 alone (treatment A)
Number of subjects: 12
Study 10071982 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m2 followed immediately by Maalox (treatment B)
Number of subjects: 12
Study 10071982 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m2 followed 2 hours later by Maalox (treatment C)
Number of subjects: 12
Study 7551385 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O2) delivered via nasal cannula at 1 L/min for 4 hours
Number of subjects: 23
Study 7551385 — intervention group
Group type: COMPARATOR
Intervention: Room air delivered via nasal cannula at 1 L/min for 4 hours
Number of subjects: 23
Study 1971651 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pre-operative dose of 1 g ceftazidime (im or iv) 1 hour before surgery
Number of subjects: 120
Study 1971651 — intervention group
Group type: COMPARATOR
Intervention: Three peri-operative doses of 1 g ceftazidime (im or iv) 1 hour before, and 6 and 12 hours after surgery
Number of subjects: 120
Study 6992979 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized radiotherapy (4000 rad)
Number of subjects: 114
Study 6992979 — intervention group
Group type: COMPARATOR
Intervention: Extensive radiotherapy including brain, adrenals, and upper retroperitoneal lymph nodes
Number of subjects: 114
Study 30395857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonheparin coating (Balance; Medtronic)
Number of subjects: 0
Study 30395857 — intervention group
Group type: COMPARATOR
Intervention: Heparin‐based coating (Carmeda; Medtronic)
Number of subjects: 0
Study 29019557 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 Group
Number of subjects: 210
Study 29019557 — intervention group
Group type: COMPARATOR
Intervention: Air Group
Number of subjects: 210
Study 25730652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling with superimposed electromyostimulation (C+E)
Number of subjects: 13
Study 25730652 — intervention group
Group type: COMPARATOR
Intervention: Cycling (C)
Number of subjects: 13
Study 25730652 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (E)
Number of subjects: 13
Study 25393603 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative visual feedback (Group 1)
Number of subjects: 97
Study 25393603 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative visual feedback (Group 2)
Number of subjects: 97
Study 25393603 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group 2 to Group 1
Number of subjects: 97
Study 22863562 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 SNP rs738409
Number of subjects: 1532
Study 22863562 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 SNP rs2281135
Number of subjects: 1532
Study 22863562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-specific association
Number of subjects: 1532
Study 19653486 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent auditory cues
Number of subjects: 0
Study 19653486 — intervention group
Group type: COMPARATOR
Intervention: Incongruent auditory cues
Number of subjects: 0
Study 19653486 — intervention group
Group type: EXPERIMENTAL
Intervention: Egocentric auditory cues
Number of subjects: 0
Study 19653486 — intervention group
Group type: EXPERIMENTAL
Intervention: Exocentric auditory cues
Number of subjects: 0
Study 17461296 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 6600
Study 17461296 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day in patients with type 2 diabetes
Number of subjects: 6600
Study 17461296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6600
Study 16118611 — intervention group
Group type: EXPERIMENTAL
Intervention: O2/N2O mixture
Number of subjects: 34
Study 16118611 — intervention group
Group type: COMPARATOR
Intervention: O2/air mixture
Number of subjects: 34
Study 12064363 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF donor priming (3 to 4 micro/kg per day for 7 days prior to marrow harvest)
Number of subjects: 50
Study 12064363 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF donor priming
Number of subjects: 50
Study 9800936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies against copper-oxidised LDL
Number of subjects: 34
Study 9800936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies against MDA-LDL
Number of subjects: 34
Study 7895137 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated informational message directed to physicians regarding average LOS and current LOS.
Number of subjects: 14099
Study 7895137 — intervention group
Group type: COMPARATOR
Intervention: No message (control group).
Number of subjects: 14099